Click Therapeutics Gains FDA marketing authorization for Innovative Migraine Treatment
On April 15th, Click Therapeutics announced FDA marketing authorization of CT-132, a prescription digital therapeutic (PDT) for the preventive treatment of episodic migraine. This solution reflects the growing maturity of clinically validated digital therapeutics in mainstream medicine.
We have welcomed Click Therapeutics on our stage many times to share its pioneering work in digital therapeutics.
At Frontiers Health 2019, their CEO, David Benshoof Klein, focused on the innovative approach of using digital therapeutics as prescription medical treatments. In 2020, he joined our virtual stage to share some insights on how PDTs can increase access to care and reduce systemic health barriers. Most recently, at Frontiers Health 2024, David Benshoof Klein introduced the concept of "software-enhanced drugs," which combine traditional pharmacotherapy with digital therapeutics to create new dosage forms.
DATE: April 15th, 2025 | SOURCE: Click Therapeutics
Join us and our global community of health innovators in Berlin on November 11-12, 2025.